

## In-house age-specific reference ranges for free light chains measured on the SPAPLus® analyser

Campbell, Lauren; Simpson, Dawn; Shields, Adrian; Ferry, Berne; Ramasamy, Karthik ; Sadler, Ross

DOI:

[10.1177/0004563219899421](https://doi.org/10.1177/0004563219899421)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Campbell, L, Simpson, D, Shields, A, Ferry, B, Ramasamy, K & Sadler, R 2019, 'In-house age-specific reference ranges for free light chains measured on the SPAPLus® analyser', *Annals of Clinical Biochemistry*.  
<https://doi.org/10.1177/0004563219899421>

[Link to publication on Research at Birmingham portal](#)

### Publisher Rights Statement:

© 2020, SAGE Publications.

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

**In-house age-specific reference ranges for free light chains measured on the SPAPLus® analyser**

Lauren Campbell<sup>1</sup>, Dawn Simpson<sup>1</sup>, Adrian Shields<sup>2</sup>, Berne Ferry<sup>3</sup>, Karthik Ramasamy<sup>1</sup>, Ross Sadler<sup>1</sup>

<sup>1</sup>Oxford University Hospitals NHS Foundation Trust

<sup>2</sup>University Hospitals Birmingham NHS Foundation Trust

<sup>3</sup> National School of Healthcare Science, UK

Abstract word count: 219

Total Word Count: 2489

Table Count: 2

Figure Count: 2

Key words

Serum free light chains, multiple myeloma, demand management, reference ranges, eGFR

**Declaration of conflicting interests**

None

**Funding**

The research was funded internally as part of a service evaluation approved by the Oxford University Hospitals NHS Foundation Trust R&D department.

**Ethical Approval**

Not Applicable

**Guarantor**

LC

**Contributorship**

RS, KR, LC and BF conceived the study. LC and DS analysed samples and compiled data. RS, AS and LC analysed data and drafted the paper. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

**Acknowledgements**

None

## Abstract

**Background:** The measurement of monoclonal free light chains is being increasingly utilised since the introduction of serum based assays. It is important for laboratories to determine their own reference ranges in order to reflect the local population. The aim of this study was to determine if age-adjusted reference ranges for serum free light chains would have implications for demand management of further laboratory investigations including immunofixation.

**Methods:** After certain exclusions, 4293 samples from individuals seen in primary care across Oxfordshire between 2014–2016 were identified for analysis of patient characteristics, serum free light chain results and estimated glomerular filtration rate.

**Results:** We found age to be an independent variable when considering serum free light chain concentrations, ratio and estimated glomerular filtration rate. The reference ranges derived from our data differ markedly from the original Binding Site ranges. When the age-specific ranges are retrospectively applied to our population there is a 38% decrease in follow up testing with no loss of specificity.

**Conclusion:** We feel confident implementing new age-specific serum free light chain reference ranges in our laboratory. We have developed a simple algorithm for evaluating serum free light chains based on age and estimated glomerular filtration rate. We encourage laboratories to establish their own local reference ranges using large cohorts and their chosen serum free light chain assay platform.

## **Background**

The detection of monoclonal free light chains has historically been performed by urine electrophoresis, conducted alongside the serum investigations. Obtaining urine samples for immunological investigations from patients is challenging; studies from both primary and secondary care have shown that, at best, only 40% of patients have urine electrophoresis performed and in some studies, this is as low as 5%.<sup>1, 2</sup>

Serum free light chain (FLC) assays allow the identification and quantification of kappa and lambda immunoglobulin FLCs and indirect determination of monoclonality using the kappa:lambda ratio (FLCr).<sup>3</sup> Novel disease classifications have arisen using these methods including light chain MGUS, defined by the absence of paraprotein by serum protein electrophoresis (SPEP) and serum immunofixation (IFE) and presence of abnormal FLCr and raised FLC concentrations.<sup>4</sup>

In 2016, the NICE guidelines for myeloma diagnosis and management recommended the introduction of FLC measurement (alongside SPEP) into the myeloma diagnostic algorithm, “to confirm the presence of a paraprotein indicating possible myeloma or monoclonal gammopathy of undetermined significance (MGUS)”.<sup>5</sup> These guidelines also recommend performing IFE on all samples with abnormal FLCr. Both recommendations highlight the importance of having accurate reference ranges which reflect the population being tested. The 2009 International Myeloma Working Group (IMWG) guidelines recommend treating myeloma patients with LC ratio of >100 in the absence of other CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions) due to increased risk of progression to active myeloma.<sup>6</sup>

Accordingly, FLC measurements are now the standard of care for patients with plasma cell dyscrasias. In primary care the FLC assay can aid decision making regarding further laboratory investigations, including IFE, and onward referral to secondary care. In secondary care, FLC measurement can aid the diagnosis, prognostication and on-going management of patients with plasma cell dyscrasias.

The Freelite (The Binding Site, UK) assay is a turbidimetric assay which uses polyclonal antibodies directed at epitopes of the FLC constant region which are hidden in intact immunoglobulins; therefore only light chains which are unbound to a heavy chain are quantified. The reference range supplied by The Binding Site (Birmingham, UK) for FLCr is 0.26-1.65 (kappa concentration: 3.30-19.40mg/L, lambda concentration: 5.71-26.30mg/L using the 95<sup>th</sup> percentile). This data was obtained from a limited number of samples (282 normal subjects aged 20 to 90 years) and was intended for guidance purpose only.<sup>7</sup> The FLCr range supplied by The Binding Site is used in the IMWG diagnostic criteria for light-chain MGUS and therefore has an impact on both the diagnosis and monitoring of this disorder.<sup>8</sup>

The aim of this study was to generate age-adjusted reference ranges for FLC and FLCr. As serum FLC concentrations are known to be affected by GFR, we also took the eGFR values of our cohort under consideration. By retrospectively applying the novel reference ranges to the overall cohort, we demonstrate our approach has significant implications for demand management, both in respect to further laboratory testing and referrals for secondary care.

## **Methods**

A service evaluation of laboratory diagnostics at the Immunology Laboratory, Oxford, was undertaken to evaluate the clinical utility and cost-effectiveness of screening for plasma cell dyscrasias in 4544 consecutive serum samples sent for serum protein electrophoresis from individuals seen in primary care across Oxfordshire, UK in 2014-2016.

Patients enrolled in this study were >20 years of age with no known prior history of lymphoproliferative disease, confirmed by the Laboratory Information Management System (LIMS). All samples underwent nephelometric immunoglobulin measurement (Architect C4000, Abbott) and SPEP (V8, Helena) within 3 days of receipt in the laboratory. Measurement of FLC concentrations using the SPAPlus analyser (The Binding Site, UK) and Binding Site reagents was performed within 21 days of receipt in the laboratory. This data set was used to validate the Freelite reference range provided by the Binding Site and to generate age specific reference ranges for FLC and FLCr.

The following exclusions were made: 26 samples (0.6%) were excluded because clinical details provided on the request card included chronic kidney disease (CKD); 204 (4.5%) patients were excluded because a monoclonal protein was identified on SPEP; all patients with a FLCr outside of the established Binding Site normal range underwent immunofixation (Hydrasys, Sebia) which identified a monoclonal protein in a further 21 (0.5%) patients who were also excluded.

Results from the remaining 4293 samples were taken forward for further analysis. Samples were stratified by age into four groups: 20-40 (445 patients), 41-60 (1151 patients), 61-80 (1972 patients), 81+ (725 patients). Each age group was subject to normality plotting of kappa and lambda light chain concentrations and FLCr (Analyse-it for Microsoft Excel, Version 2.20, Analyse-it Software, Ltd) to dismiss samples that could represent patients with significant disease. The normally distributed region of each group was then selected and a 2.5<sup>th</sup>-97.5<sup>th</sup> percentile analysis carried out to define normal ranges for serum free kappa and lambda concentrations and FLCr.

Figure 1 shows an example of the Normal Q-Q plot for kappa light chain concentrations in the 20-40 age group. As renal impairment can significantly affect FLC concentrations, eGFR values were calculated based on serum creatinine assayed within 3 months of the FLC samples, utilising the 'Modification of Diet in Renal Disease (MDRD)'-formula.<sup>9</sup>

One-way ANOVA analysis was carried out for the four variables (kappa concentration, lambda concentration, FLCr and eGFR) between the four age groups. A *P*-value of <0.05 was considered significant.

[Insert Figure 1 and legend]

## Results

The median age within the cohort was 67 years (range 20-102), with 59% of the samples originating from females. When modelling the data, both Age vs FLCr ( $r = 0.29$ ,  $P < 0.001$ , 95% CI [0.27, 0.32]) and eGFR vs FLCr ( $r = -0.24$ ,  $P < 0.001$ , 95% CI [-0.27, -0.22]) relationships were found to be linear.

Table 1 shows the range of free kappa concentration, free lambda concentration, FLCr and eGFR generated from the entire cohort with 2.5<sup>th</sup>-97.5<sup>th</sup> percentile analysis performed prior to normality plotting.

**Table 1.** Free light chain concentration and ratio by age range for the entire cohort prior to normality plotting.

Age Range (years)	<i>n</i>	Kappa Range mg/L	Lambda Range mg/L	FLCr Range	eGFR Range ml/min/1.73m <sup>2</sup>
20-40	445	5.0 – 23.0	5.3 – 27.2	0.46 – 1.55	39 - >90
41-60	1151	5.4 – 29.0	5.5 – 28.9	0.50 – 1.95	34 - >90
61-80	1972	6.4 – 43.6	6.0 – 36.0	0.60 – 2.0	25 - >90
81+	725	8.6 – 60.8	6.7 – 47.8	0.67 – 2.4	21 - >90

*n* = number of individuals

Table 2 shows the range of free kappa concentration, free lambda concentration, FLCr and eGFR generated from the normally distributed cohort, following normality plotting with the 2.5<sup>th</sup>-97.5<sup>th</sup> percentile analysis performed. The data presented in Table 2 represent the normal reference ranges we consider to be useful and have adopted in clinical practice.

**Table 2.** Free light chain concentrations, free light chain ratio and eGFR by age range for the normally distributed 2.5<sup>th</sup> – 97.5<sup>th</sup> percentile cohort.

Age Range (Years)	Kappa Range mg/L	<i>n</i>	Lambda Range mg/L	<i>n</i>	FLCr Range	<i>n</i>	eGFR Range ml/min/1.73m <sup>2</sup>	<i>n</i>
20-40	7.5 – 16.8	328	9.1 – 20.2	305	0.73 – 1.48	293	63 - >90	407
41-60	9.6 – 21.6	725	9.8 – 22.6	750	0.87 – 1.45	678	58 - >90	1079
61-80	11.3 – 27.6	1238	10.3 – 24.4	1307	0.99 – 1.80	1260	40 - >90	1864
81+	14.2 – 37.0	451	13.7 – 38.0	448	1.0 – 1.80	480	27 - >90	709

$n$  = number of individuals

Using the normally distributed data in Table 2, one way ANOVA analysis of the different age groups reveals significant differences between each age group ( $P < 0.001$ ) for all variables (kappa concentration, lambda concentration, FLCr and eGFR). No statistically significant relationship was observed between gender and any of the variables.

Figure 2 shows the prevalence data for eGFR ranges within each age group after normality plotting and 2.5<sup>th</sup>-97.5<sup>th</sup> percentile analysis. A normal eGFR is considered to be  $\geq 60 \text{ ml/min/1.73m}^2$ . The prevalence of eGFRs within CKD classifications 3-4 (which are classified by progressively worsening renal impairment starting as eGFR  $< 60 \text{ ml/min/1.73m}^2$ ) increased with age, however no patients in the cohort had an eGFR within the CKD 5 range ( $< 15 \text{ ml/min/1.73m}^2$ ). This is likely to reflect the fact that these patients are principally managed in secondary, not primary care. None of the patients with eGFR  $< 60 \text{ ml/min/1.73m}^2$  can be classified as having CKD without other markers of kidney disease being present. The eGFR prevalence by age results from our analysis are concordant with those found by a large retrospective study calculating eGFR in primary care patients from Oxfordshire.<sup>10</sup>

[Insert Figure 2 and legend]

The 2016 NICE guidelines recommend performing serum IFE on any patients with an abnormal SPEP or FLCr.<sup>5</sup> We retrospectively applied the new normally distributed FLCr and eGFR ranges to the data. Based on the Binding Site FLCr ranges, 410 patients underwent serum IFE. Using our new reference ranges 254 patients would have undergone serum IFE, representing a 38% reduction. The new reference ranges would have failed to identify four patients with small paraproteins only identified by serum IFE. Two year follow up of these patients shows no evidence of a persistent monoclonal gammopathy, suggesting these paraproteins were transient, reactive phenomena.

## **Conclusion**

The establishment of normal reference ranges is essential to allow the meaningful interpretation of laboratory investigations. We measured FLC in over 4000 primary care patients sent for immunoglobulin testing using the Binding Site Freelite platform. We demonstrate significantly different normal reference ranges for serum free kappa concentration, serum free lambda concentration and the kappa/lambda ratio based on an individual's age. This contrasts with previous smaller studies that found age was not an independent variable when considering serum free light chain concentrations.<sup>3, 11</sup> Both of these studies enrolled less than 150 patients and were likely underpowered to identify such differences

In our population renal impairment consistent with CKD stages 3-5 increased with age, as previously show.<sup>12</sup> The eGFR age-specific ranges produced by our data concur with age-specific values produced from over 3500 non-diseased Caucasian participants in the Netherlands.<sup>12</sup> As accurate classification of CKD stages 3-5 requires decreased eGFR values over a minimum period of 3 months we are unable to determine the true prevalence

of CKD within the study population. Nevertheless, we did determine a weak inverse association between renal function as assessed by eGFR and serum free light chain ratio. This is in concordance with previous work assessing FLC in patients with CKD but without monoclonal gammopathy.<sup>9</sup> It was found that these patients had higher FLCr when compared to the original healthy volunteer range. From this work on patients in renal failure a new 'normal' FLCr range (0.37-3.1) was proposed for patients with renal impairment, regardless of age, and is currently in use in our laboratory.<sup>9, 13</sup>

The National Kidney Foundation (NKF) recommends a cut-off of 60ml/min/1.73m<sup>2</sup> or below to categorise a patient as having CKD.<sup>14</sup> However, the CKD classification guidelines produced by the NKF make no distinction based on either age or gender. The MDRD equation used to calculate eGFR was developed using nephrology referral patients with elevated serum creatinine levels<sup>15</sup>; however, it has been found to have a more limited use for the general population, underestimating GFR in healthy subjects.<sup>16</sup>

It has been shown a number of times that GFR declines with normal aging<sup>12, 17</sup>, with a decline of approximately 5-10ml/min per decade; this compares well with our data. The study in the Netherlands showed that defining a cut-off for CKD without taking age into account can lead to misclassification, with a significant minority of mostly older healthy subjects, having an eGFR below 60 ml/min/1.73m<sup>2</sup>.<sup>12</sup> Many of the patients in our cohort who are >60 years of age would meet the NKF criteria for moderate CKD and our data show that an eGFR of 60 ml/min/1.73m<sup>2</sup> is within the normal reference range for patients aged 41 years and over.

It has previously been established that eGFR values <60ml/min/1.73m<sup>2</sup> are associated with a worse prognosis and that in the general population overall mortality risk is significantly increased below this cut off.<sup>14, 18</sup> A large cohort study however found that, although present, this association between eGFR of <60ml/min/1.73m<sup>2</sup> and mortality was far weaker in elderly subjects than in the younger age groups.<sup>19</sup> This study found that an eGFR of 50-59ml/min/1.73m<sup>2</sup> was associated with increased mortality in subjects aged 18-54 years. This compares well with our lower limit of the eGFR normal range for <60 year olds being 58ml/min/1.73m<sup>2</sup>. From the extensive data, this study suggested that mortality risk stratification should not be based on the same eGFR cut-off points for all ages, and proposed an eGFR cut-off between 30-59ml/min/1.73m<sup>2</sup> for elderly patients. This also compares well with our data for both the 61-80 years and 81+ years age groups and the data produced in the Netherlands study.<sup>12</sup>

Within our primary care population, we hypothesise that a decline in renal function and an increase in subclinical non-renal illnesses with age will contribute to the increased FLC ranges seen in this study and this will not lead to false normal results. To ensure this we performed a two year follow up on all patients through laboratory records, and found no patients with FLCr within the new normal ranges had developed a plasma cell dyscrasia.

As we have used a primary care population, rather than a healthy control population to calculate these ranges it is possible that patients with non-renal illnesses can have raised FLC concentrations. However these raised concentrations have so far been seen to either not affect FLCr or result in only a borderline increased FLCr.<sup>20-22</sup>



Our ranges varied from those stated in the Binding Site kit insert and have time and cost implications for the laboratory, as shown by the reduction of serum IFEs needing to be performed. For our data set, this reduction is exclusively due to the adjustment of the FLCr ranges for our different age groups. Notably, FLC assays have been shown to be platform dependent<sup>23</sup> and so these ranges can only apply to samples being tested on the SPAPlus analyser using the Binding Site reagents. We generated this data using a primary care population as a substitute for a large healthy control population. We believe that these ranges can also be applied to patients in secondary care being screened for monoclonal gammopathies, with renal impairment being taken into account. A study in tertiary care samples found a high false positive FLCr rate in those without a monoclonal gammopathy when using the original Binding Site FLC reference ranges.<sup>24</sup> This supports the data we have found in our primary care population and suggests that our alternative ranges can be applied across the different care cohorts. We encourage laboratories to establish their own local reference ranges using large cohorts and their chosen FLC platform.

With our follow up indicating no missed plasma cell dyscrasia patients, we can be confident in implementing these ranges into our routine practice with the aim to reduce the number of unnecessary follow up tests and referrals for patients being screened with SPEP and FLC in line with the 2016 NICE guidelines.<sup>5</sup> From both our data analysis and previous data we feel age-specific eGFR values should be used when screening patients for monoclonal gammopathy. We feel confident in setting new eGFR cut-off limits, below which to use the previously calculated FLCr renal reference range.<sup>9, 13</sup> These cut-offs remain at <60ml/min/1.73m<sup>2</sup> for patients aged 60 years and below, but decrease to <40ml/min/1.73m<sup>2</sup> for patients aged 61 years and over.

Accordingly, we have developed an algorithm for interpreting FLC results and determining whether further investigation with IFE is warranted in the presence of a normal SPEP. If a patient has significant renal dysfunction as defined by the eGFR cut-off for their age (<60ml/min/1.73m<sup>2</sup> for patients aged 60 years and below, <40ml/min/1.73m<sup>2</sup> for patients aged 61 years and over) then the previously generated renal FLCr reference range (0.37-3.1) will be used for interpretation.

If eGFR is >60ml/min/1.73m<sup>2</sup> for patients aged 60 years and below, or >40ml/min/1.73m<sup>2</sup> for patients aged 61 years and over, then the age adjusted ranges calculated from patients where significant renal dysfunction had been excluded will be used (Table 2). This should reduce patients inappropriately being labelled as light-chain MGUS, reduce the need for long-term follow up and monitoring, and reduce the burden of further laboratory investigation of ostensibly normal results.

## References

1. Hill PG, Forsyth JM, Rai B and Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. *Clinical chemistry*. 2006; 52: 1743-8.

2. Robson E, Taylor J, Beardsmore C, Basu S, Mead G and Lovatt T. Utility of Serum Free Light Chain Analysis When Screening for Lymphoproliferative Disorders: The Experience at a District General Hospital in the United Kingdom. *Labmedicine*. 2009; 40: 325-9.
3. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. *Clinical chemistry*. 2001; 47: 673-80.
4. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet (London, England)*. 2010; 375: 1721-8.
5. NICE. Myeloma: diagnosis and management. *NICE Guideline*. 2016; NG35.
6. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*. 2009; 23: 215-24.
7. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. *Clinical chemistry*. 2002; 48: 1437-44.
8. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *The Lancet Oncology*. 2014; 15: e538-48.
9. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. *Clinical journal of the American Society of Nephrology : CJASN*. 2008; 3: 1684-90.
10. Callaghan CA, Shine B and Lasserson DS. Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting. *BMJ Open*. 2011; 1: e000308.
11. Galvani L, Flanagan J, Sargazi M and Neithercut WD. Validation of serum free light chain reference ranges in primary care. *Annals of clinical biochemistry*. 2016; 53: 399-404.
12. Wetzels JF, Kiemeny LA, Swinkels DW, Willems HL and den Heijer M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. *Kidney international*. 2007; 72: 632-7.
13. Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. *BMC nephrology*. 2008; 9: 11.
14. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney international*. 2011; 80: 17-28.
15. Kusek JW, Coyne T, de Velasco A, et al. Recruitment experience in the full-scale phase of the Modification of Diet in Renal Disease Study. *Controlled clinical trials*. 1993; 14: 538-57.
16. Poggio ED, Wang X, Greene T, Van Lente F and Hall PM. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. *Journal of the American Society of Nephrology : JASN*. 2005; 16: 459-66.
17. Rule AD, Gussak HM, Pond GR, et al. Measured and estimated GFR in healthy potential kidney donors. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2004; 43: 112-9.
18. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet (London, England)*. 2010; 375: 2073-81.
19. O'Hare AM, Bertenthal D, Covinsky KE, et al. Mortality risk stratification in chronic kidney disease: one size for all ages? *Journal of the American Society of Nephrology : JASN*. 2006; 17: 846-53.
20. Redegeld FA, Thio M and Groot Kormelink T. Polyclonal immunoglobulin free light chain and chronic inflammation. *Mayo Clinic proceedings*. 2012; 87: 1032-3.
21. Dispenzieri A, Katzmann JA, Kyle RA, et al. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. *Mayo Clin Proc*. 2012; 87: 517-23.

22. Piehler AP, Gulbrandsen N, Kierulf P and Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. *Clinical chemistry*. 2008; 54: 1823-30.
23. Lock RJ, Saleem R, Roberts EG, et al. A multicentre study comparing two methods for serum free light chain analysis. *Annals of clinical biochemistry*. 2013; 50: 255-61.
24. Singh G. Serum Free Light Chain Assay and  $\kappa/\lambda$  Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate. *American Journal of Clinical Pathology*. 2016; 146: 207-14.